PT  - JOURNAL ARTICLE
AU  - Helwick, Caroline
ED  - Nissen, Steven
TI  - Torcetrapib Fails to Meet Expectations
DP  - 2007 Jun 01
TA  - MD Conference Express
PG  - 17--20
VI  - 7
IP  - 1
4099  - http://mdc.sagepub.com/content/7/1/17.short
4100  - http://mdc.sagepub.com/content/7/1/17.full
AB  - Increased levels of high-density lipoprotein cholesterol decrease the risk of cardiovascular disease. Torcetrapib, a cholesteryl-ester-transfer protein inhibitor, has a potent effect on increasing HDL-C levels that was hoped would translate into the halting or reversal of atherosclerosis. The results from three clinical trials of torcetrapib are discussed in this article.